By Erewunmi Peace

The Federal Government of Nigeria has announced the arrival of Lenacapavir, a long-acting injectable drug designed to help prevent HIV/AIDS.

Health officials said the introduction of the drug marks a major step in strengthening the country’s HIV prevention strategy, particularly for individuals who are at higher risk of infection.

According to the government, Lenacapavir will be used as part of Pre-Exposure Prophylaxis (PrEP) programmes aimed at reducing the number of new HIV infections across the country.

The initiative is being implemented through the National AIDS, Viral Hepatitis and STIs Control Programme (NASCP) under the supervision of the Federal Ministry of Health and Social Welfare.

Health experts say Lenacapavir is unique because it is a long-acting injection that can provide protection for several months, reducing the need for daily preventive medication and improving adherence among users.

Authorities believe the availability of the drug will significantly strengthen ongoing efforts to control HIV transmission and improve public health outcomes in Nigeria.

Nigeria continues to expand access to HIV prevention and treatment services as part of broader national and global efforts to end the HIV epidemic.